Table of Contents
Key Points
- Stephen Saad’s stake in Aspen Pharmacare drops below $450 million as shares slide 12.82% on the JSE over the past 15 trading days.
- Aspen’s market cap declines to $3.4 billion, impacting shareholder wealth, including a $62.85 million loss for Saad in just two weeks.
- Aspen shares drop 11.37% in 2025, turning a $100,000 investment into $88,630, amid broader market pressures.
South African pharma tycoon Stephen Saad, CEO of Aspen Pharmacare, Africa’s largest pharmaceutical company, has seen the value of his stake in the company drop below $450 million, as the company’s shares continue to slide on the Johannesburg Stock Exchange (JSE).
Saad, who owns 12.8 percent of the Durban-based drugmaker—equivalent to 57,221,750 shares—has lost about R1.23 billion ($62.85 million) over the past 15 days. This brings the value of his Aspen stake to just $434.35 million.
The recent decline follows a previous loss of $41.15 million between Jan. 31 and Mar. 27, when the value of his holdings had already fallen to R9.58 billion ($525.19 million).
Aspen's market cap drops 12.82%
Aspen Pharmacare, founded by Stephen Saad in 1997, has become a prominent player in South Africa’s pharmaceutical industry, contributing significantly to his wealth. The company operates in more than 115 countries and has experienced steady growth under his leadership.
However, Aspen's share price has fallen by 12.82% on the Johannesburg Stock Exchange over the past 15 days, dropping from R167.59 ($8.71) on March 10 to R146.11 ($7.59). This decline has reduced the company’s market capitalization to around $3.4 billion, resulting in significant losses for shareholders.
As a result, the value of Saad’s stake in Aspen has taken a hit. The market value of his holdings dropped by R1.23 billion ($62.85 million), falling from R9.59 billion ($498.2 million) on March 10 to R8.36 billion ($434.35 million) as of the latest report.
Your Money and your life
So far in 2025, Aspen’s shares have fallen by 11.37 percent. If you invested $100,000 at the beginning of the year, it would now be worth approximately $88,630—marking a loss of $11,370 amid broader market pressures.
